Thesis TrackerLoading companies…
All companies
Loading…
Thesis TrackerThesis TrackerLoading…
EBOS Group (ASX:EBO), the healthcare and animal care distributor, has faced earnings pressure, though some fund managers continue to back the franchise. In June 2026, Yarra Capital Management, which holds an overweight position, noted a negative trading update in which higher fuel and energy costs weighed on the wholesale pharmacy business. Mint Asset Management has continued to add to EBOS on share price weakness. EBOS Group operates in the Healthcare sector within the Healthcare Providers and Services industry, and Thesis Tracker has captured 2 comments from 2 fund managers, Yarra Capital Management and Mint Asset Management. Founded in 1922 and headquartered in Docklands, Melbourne, EBOS distributes pharmaceuticals, medical consumables and animal care products across Australia and New Zealand, and operates retail pharmacy and veterinary brands.
Company figures as of 15 Oct 2026. For information only.
Fund managers including Cooper Investors, Mint Asset Management, Airlie Funds Management and Yarra Capital Management have invested in EBOS Group Ltd (ASX:EBO).
Mint Asset Management has continued adding to EBOS on weakness, and Yarra Capital Management retains an overweight position, suggesting fund managers see value in the underlying healthcare and animal care distribution franchise.
Yarra reported a 2% earnings downgrade linked to higher fuel and energy costs in the wholesale pharmacy division, which weighed on the shares.
EBOS Group Ltd. is a healthcare and animal care company founded in 1922, headquartered in Docklands, Australia. The company operates through three segments: Healthcare, Animal Care, and Corporate. The Healthcare and Animal Care divisions manage wholesale, retail, and own-brand product distribution across diverse sectors. The Corporate segment includes central administration and net funding costs. EBOS Group provides integrated products and services, maintaining a focus on healthcare and veterinary markets.
General information only. Thesis Tracker reports what named fund managers have published about ASX companies. It does not take into account your objectives, financial situation or needs, and is not financial product advice or a recommendation to buy, sell or hold any security.
11,356 comments from 164 managers on 761 companies, snapshot 15 Oct 2026.